Sign up to save your podcasts
Or
Share Audio Journal of Oncology Podcast
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Audio Journal of Oncology Podcast episodes
- David R Spigel MD; ASCO 2026: Bispecific PD-1/VEGF Antibody Ivonescimab Extends Life in Patients with Untreated Advanced Non–Small Cell Lung Cancer: Phase 3 HARMONi-6 trialCHICAGO, USA—The bispecific antibody ivonescimab (that targets the PD-1 and VEGF molecules) has extended overall survival in patients with untreated advanced squamous non-small cell lung cancer in the latest data from the HARMONi-6 trial reported at the 2026 Annual Meeting of the American Society of Clinical Oncology by Chen Zhiwei from Jiao Tong University in Shanghai, China.Peter Goodwin discusses the findings with ASCO expert David R Spigel MD, President & Chief Medical Officer at the Sarah Cannon Research Institute in Nashville, Tennessee, USA7 min
- Zachary Avigan MD; IMS 2026: Predicting Multiple Myeloma Cure: Ultra-Low-Risk Patients Who Have Favorable Outcomes and Can Stop TherapyGLASGOW, Scotland—Patients who achieved sustained measurable residual disease negativity for more than 24 months had significantly improved survival outcomes and could be categorized as cured. This isthe implication of findings from a retrospective analysis looking at predicting cure in myeloma reported at the International Myeloma Society 2026 Annual Meeting.Sarah Maxwell heard the details from study author Zachary Avigan MD, Assistant Professor of Medicine in the Division of Hematology and Medical Oncology at Icahn School of Medicine in Mount Sinai Hospital, New York City, USA.10 min
- Thomas E. Stinchcombe MD; CSCO 2026: The Journal of Clinical Oncology’s Mission and Vision Going Forwards: New Editor's Global PerspectiveJINAN, China—January 2027 sees the appointment of the new Editor-in-Chief of the Journal of Clinical Oncology who tells us (during his visit to China) he is committed to continue the policy of global co-operation in clinical cancer research publishing.He is: Thomas Eldridge Stinchcombe MD, FASCO, Medical Oncologist and Member of the Thoracic Oncology Program at Duke Cancer Institute in Durham, North Carolina, in the USA.At the 2026 Annual Meeting of the Chinese Society of Clinical Oncology he talked about his plans with our reporter, Peter Goodwin.9 min
- Fang Wu MD PhD; CSCO 2026: Could Emotional Distress Medicines Prolong Survival in Patients with Small Cell Lung Cancer?JINAN, China—Provocative evidence is emerging that emotional distress can adversely affect outcomes among patients with lung cancer. Data from a study of the role of hormones in affecting lung cancer outcomes were reported at the 2026 Annual Meeting of the Chinese Society of Clinical Oncology in an oral communication entitled: Clinical Impact of Baseline Hormones on Outcomes of First Line Immunotherapy in Extensive Stage Small-Cell Lung Cancer.Peter Goodwin discussed the findings with first author Fang Wu MD PhD, Deputy Director, Chief Physician, Professor and Doctoral Supervisor in the Department of Oncology at the Second Xiangya Hospital Cancer Center in Central South University, Changsha, China.10 min
- Luciano J. Costa MD PhD; IMS 2026: Teclistamab plus Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma brings “Dramatic Reduction” of Progression Risk, Without Increased Risk of Death: MajesTEC-3 Phase Three Study FindingsGLASGOW, Scotland—A combination of the bi-specific T-cell engager antibody teclistamab (that targets both B-cell maturation antigen and CD-3) paired with the anti-CD-38 monoclonal antibody daratumumab markedly extended relapse-free survival, and improved overall survival among patients with relapsed or refractory multiple myeloma in comparison with standard of care triplet therapy.This was in the international multi-center phase three MajesTEC-3 study reported at the 2026 Annual Meeting of the International Myeloma Society.Sarah Maxwell caught up with lead author Luciano Costa MD PhD, Professor of Medicine and Director of the Multiple Myeloma Research and Treatment Program at the University of Alabama, in Birmingham, USA.8 min
- Feng Wang PhD MD; CSCO 2026: Progress and Prospects of New Drug Research for Colorectal Cancer: The View from ChinaJINAN, China—The 2026 Annual Meeting of the Chinese Society of Clinical Oncology, with more than 40 000 cancer clinicians attending, heard evidence from clinical trial findings and new science bringing great hope for the treatment of colorectal cancer.The era of targeted precision medicine for colorectal cancer had truly arrived, delegates heard, with a long list of potential targets identified by genetic testing, and an impressive range of promising agents to match them to treat cancer in new and more effective ways.In an abstract entitled: “Progress and Prospects of New Drug Research for Colorectal Cancer”, the latest state of the art in colorectal cancer research was assessed by Feng Wang PhD MD, Director of Medical Oncology at Sun Yat-sen University Cancer Center, in Guangzhou, China. Afterwards, she talked with our reporter, Peter Goodwin:12 min
- Philippe Moreau MD; IMS 2026: International Myeloma Society President Discusses Key Themes, Future Directions and Challenges in Newly Diagnosed Multiple MyelomaGLASGOW, Scotland—Philippe Moreau MD, President of the International Myeloma Society, talks with Audio Journal of Oncology correspondent Sarah Maxwell about the key themes, future directions and challenges in newly diagnosed multiple myeloma under discussion at the 2026 Annual Meeting, including new drugs and the prospects for cure.10 min
- Jiujie Cui MD PhD, CSCO 2026: Early Findings Show KRAS-G12D Inhibitor More than Doubles Median Overall Survival in Patients with Advanced Pancreatic CancerJINAN, China—A highly selective drug that inhibits the predominant oncogenic driver (the KRAS-G12D mutation) in advanced pancreatic ductal adenocarcinoma, and minimizes side effects, has shown big promise for keeping patients alive and progression-free. This was in early trial results reported at the 2026 Annual Meeting of the Chinese Society of Clinical Oncology.In phase 1b/2 study results, Chinese researchers reported marked improvements in outcomes that mirror the 2026 findings from the USA reported in the New England Journal of Medicine with a multi-selective RAS inhibitor. Peter Goodwin heard the latest from the study first author: medical oncologist Jiujie Cui MD PhD, from Renji Hospital at Shanghai Jiaotong University School of Medicine, in Shanghai, China.11 min
- Vanita Noronha MD; ASCO 2026: Ultra-Low Dose Immunotherapy Extends Life with Metastatic Head and Neck Cancer at Low Cost for Patients in Low and Middle Income CountriesCHICAGO, USA—Although recurrent or metastatic head and neck cancers respond well to palliative chemotherapy with immune checkpoint inhibition, this approach may be un-affordable in low and middle income countries. But a randomized phase three trial from India reported a pragmatic solution at the 2026 Annual Meeting of the American Society of Clinical Oncology.Ultra-low doses of pembrolizumab immunotherapy along with “triple oral metronomic chemotherapy” were found to bring good palliation and longer survival according to Vanita Noronha MD, Professor of Medical Oncology, Tata Memorial Hospital, Mumbai, India, as she explained to Peter Goodwin.9 min
- John Mascarenhas MD; ASCO 2026: New Janus Kinase Inhibitor Improves Myelofibrosis Outcomes When Added to Ruxolitinib Initial TherapyCHICAGO, USA—Outcomes were improved for patients with myelofibrosis in the phase 3 SENTRY trial who were randomized to have the new Janus kinase inhibitor selinexor added to their ruxolitinib initial therapy.Findings were reported at the 2026 Annual Meeting of the American Society of Clinical Oncology.Peter Goodwin got the details from first author John Mascarenhas MD, Professor of Medicine and Director of the Center of Excellence for Blood Cancers and Myeloid Disorders at the Tisch Cancer Institute, Icahn School of Medicine, in Mount Sinai, New York, NY.13 min
About Audio Journal of Oncology Podcast
From the publisher's feed
As the leading authoritative, peer-reviewed audio source of oncology clinical news for clinicians and healthcare professionals, the AJO Podcast regularly brings you exclusive interviews with the…
world's leading researchers and clinicians responsible for pushing out the boundaries of science and practice. Medicine, screening, radiotherapy, surgery, clinical trials, cancer care, epidemiology and prevention are covered impartially to give busy cancer professionals access to conversational spoken comments on the clinical implications of cancer developments in the real-world context, as practiced by cancer doctors and clinicians around the globe. The AJO Podcast originates from the Audio Journal of Oncology staffed by ex-BBC professional journalists, and mentored by world-leading cancer practitioners from bodies including the American Society of Clinical Oncology, Cancer Research UK, Istituto Nazionale dei Tumori, and Action Radiotherapy. Each podcast is produced to the highest standards of audio recording and journalism and is subject to editorial appraisal to maintain that content, balance and clinical relevance of news and comment are delivered in a manner that's easy and enjoyable for listening while travelling, taking exercise, working or just relaxing. Please contact Audio Medica with your comments and make your contribution to supporting a vibrant community of clinical cancer communicators!